Open-label Study to Assess Hospitalization Rates in Adult Schizophrenic Patients Treated With Oral Antipsychotics for 6 Months and IM Depot Aripiprazole for 6 Months, Respectively, in a Naturalistic Community Setting.

Trial Profile

Open-label Study to Assess Hospitalization Rates in Adult Schizophrenic Patients Treated With Oral Antipsychotics for 6 Months and IM Depot Aripiprazole for 6 Months, Respectively, in a Naturalistic Community Setting.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Apr 2015

At a glance

  • Drugs Aripiprazole (Primary) ; Antipsychotics
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Acronyms ARRIVE-US
  • Sponsors Otsuka Pharmaceutical Development & Commercialization
  • Most Recent Events

    • 21 Oct 2014 Results presented at the 27th Annual Congress of the European College of Neuropsychopharmacology.
    • 07 Nov 2013 Planned end date changed from 1 Nov 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 09 Oct 2013 Results presented at the 26th Annual Congress of the European College of Neuropsychopharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top